Načítá se...
Development of molecular and pharmacological switches for chimeric antigen receptor T cells
The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality can also be associated with serious adverse events in the form of cytokine release syndrome....
Uloženo v:
| Vydáno v: | Exp Hematol Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6833279/ https://ncbi.nlm.nih.gov/pubmed/31709128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0151-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|